PSORIASIS Is ustekinumab superior to etanercept for psoriasis?

被引：6

作者：

Kuhn, Annegret ^{[1
]}

Luger, Thomas A. ^{[1
]}

机构：

[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany

来源：

NATURE REVIEWS RHEUMATOLOGY | 2010年 / 6卷 / 09期

关键词：

INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; TNF INHIBITION; TRIAL; EFFICACY; SAFETY;

D O I：

10.1038/nrrheum.2010.134

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe psoriasis found that ustekinumab was superior to high-dose etanercept over a 12-week period; however, several questions remain to be addressed.

引用

页码：500 / 501

页数：3

共 50 条

[41] Exacerbation of Infliximab-Induced Palmoplantar Psoriasis Under Ustekinumab Therapy in a Patient With Ankylosing Spondylitis
Safa, Gilles
Martin, Antoine
Darrieux, Laure
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (07) : 385 - 386
[42] Ustekinumab A New Option in Psoriasis Therapy
Chien, Anna L.
Elder, James T.
Ellis, Charles N.
DRUGS, 2009, 69 (09) : 1141 - 1152
[43] Ustekinumab for the treatment of psoriasis: an evidence update
Yiu, Zenas Z. N.
Warren, Richard B.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (03) : 143 - 147
[44] Ustekinumab A human monoclonal antibody for the treatment of plaque psoriasis
Phung, Olivia J.
White, C. Michael
Coleman, Craig I.
FORMULARY, 2009, 44 (03) : 72 - 76
[45] Ustekinumab: A Review in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
Zaghi, Daniel
Krueger, Gerald G.
Duffin, Kristina Callis
JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (02) : 160 - 167
[46] Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Van Voorhees, Abby S.
Mason, Marc A.
Harrold, Leslie R.
Guo, Ning
Guana, Adriana
Tian, Haijun
Herrera, Vivian
Strober, Bruce E.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (08) : 907 - 915
[47] Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience
Chiricozzi, Andrea
Conti, Andrea
Burlando, Martina
Odorici, Giulia
Gaiani, Francesca
Panduri, Salvatore
Malagoli, Piergiorgio
DERMATOLOGY, 2019, 235 (03) : 213 - 218
[48] Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment
Jacobs, A.
Rosumeck, S.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2015, 40 (07) : 810 - 811
[49] Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
Zhao, Yue
Lai, Wei
PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 865 - 872
[50] Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis
Rodriguez-Fernandez, Karine
Zarzoso-Foj, Javier
Saez-Bello, Marina
Mateu-Puchades, Almudena
Martorell-Calatayud, Antonio
Merino-Sanjuan, Matilde
Gras-Colomer, Elena
Climente-Marti, Monica
Mangas-Sanjuan, Victor
PHARMACEUTICS, 2024, 16 (10)

← 1 2 3 4 5 →